Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulindac Sulfoxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.69 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.69 |
| ▸ | PPARG | P37231 | 14/20 | 0.78 |
| ▸ | RXRA | P19793 | 6/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | EDNRA | P25101 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | DRD1 | P21728 | 1/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulindac SCHEMBL4203 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL30901384 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL31324645 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL4202 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL2029754 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL29360981 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL6903607 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL30989491 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac Sulfoxide SCHEMBL11255653 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL15700834 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140057959-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | UNIVERSIDADE ESTADUAL PAULISTA JULIO DE MESQUITA FILHO - UNESP (BR) | 2014-02-27 | — | — | US | claimed |
| US-20110118303-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | EMS S.A. (BR) | 2011-05-19 | — | — | US | claimed |
| US-20080207751-A1 | Sulindac Derivatives for Treatment of Cancer | SULFIDRIS S.R.L. (IT) | 2008-08-28 | — | — | US | claimed |
| EP-1904440-A1 | SULINDAC DERIVATIVES FOR TREATMENT OF CANCER | Sulfidris S.r.l. (IT) | 2008-04-02 | — | — | EP | claimed |
| EP-1879891-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY | Nycomed GmbH (DE) | 2008-01-23 | — | — | EP | claimed |
| EP-1877410-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY | Nycomed GmbH (DE) | 2008-01-16 | — | — | EP | claimed |
| CN-1923797-A | Pharmaceutical compounds | NICOX SA (FR) | 2007-03-07 | — | — | CN | claimed |
| US-7186753-B1 | Pharmaceutical compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | claimed |
| WO-2006134489-A1 | SULINDAC DERIVATIVES FOR TREATMENT OF CANCER | SULFIDRIS S.R.L. (IT) | 2006-12-21 | — | — | WO | claimed |
| WO-2006117316-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE US ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY | NYCOMED GMBH (DE) | 2006-11-09 | — | — | WO | claimed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| EP-0700288-B1 | INHIBITION OF HAIR GROWTH | GILLETTE CO (US) | 2001-07-18 | — | — | EP | claimed |
| EP-0405602-A1 | New Zinc derivatives of anti-inflammatory drugs having improved therapeutic activity | LABORATORIOS VINAS S.A. (ES) | 1991-01-02 | — | — | EP | claimed |
| EP-0012621-B2 | ANALGESIC COMPOSITION COMPRISING ACETAMINOPHEN AS A POTENTIATING AGENT | McNeilab, Inc. (US) | 1989-03-22 | — | — | EP | claimed |
| EP-0012621-B1 | ANALGESIC COMPOSITION COMPRISING ACETAMINOPHEN AS A POTENTIATING AGENT | McNeilab, Inc. (US) | 1983-06-08 | — | — | EP | claimed |
| US-4307114-A | TREATING DIABETES COMPLICATION | AYERST, MCKENNA & HARRISON, INC. (CA) | 1981-12-22 | — | — | US | claimed |
| US-4233457-A | Process for preparing indenyl acetic acids | MERCK & CO., INC. (US) | 1980-11-11 | — | — | US | claimed |
| EP-0012621-A1 | Analgesic composition comprising acetaminophen as a potentiating agent | McNeilab, Inc. (US) | 1980-06-25 | — | — | EP | claimed |
| US-4207340-A | Analgesic potentiation | MCNEILAB, INC. (US) | 1980-06-10 | — | — | US | claimed |
| US-3970693-A | Process for preparing indene acetic acids | MERCK & CO., INC. (US) | 1976-07-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057959-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | TPMT, UTS2R, NSUN3 | PTGS2 217/4885PTGS1 44/4885PPARG 3605/4885 |
| US-20080207751-A1 | Sulindac Derivatives for Treatment of Cancer | PTGES3, PTGES2, PTGS1 | PTGS2 4/4885PTGS1 3/4885PPARG 172/4885 |
| US-20110118303-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | TPMT, UTS2R, NSUN3 | PTGS2 217/4885PTGS1 44/4885PPARG 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.